Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLSI 
Greenwich Lifesciences Inc (GLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GLSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $42
1 Year Target Price $42
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.43% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.06M USD | Price to earnings Ratio - | 1Y Target Price 42 |
Price to earnings Ratio - | 1Y Target Price 42 | ||
Volume (30-day avg) 1 | Beta 3.16 | 52 Weeks Range 8.06 - 16.50 | Updated Date 08/29/2025 |
52 Weeks Range 8.06 - 16.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date 2025-08-29 | When - | Estimate -0.24 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -219.03% | Return on Equity (TTM) -491.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155939998 | Price to Sales(TTM) - |
Enterprise Value 155939998 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -21.23 | Shares Outstanding 13630300 | Shares Floating 6374462 |
Shares Outstanding 13630300 | Shares Floating 6374462 | ||
Percent Insiders 51.3 | Percent Institutions 10.45 |
Upturn AI SWOT
Greenwich Lifesciences Inc
Company Overview
History and Background
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences after surgery. Founded with a focus on cancer immunotherapy, the company has primarily concentrated on advancing GP2 through clinical trials.
Core Business Areas
- GP2 Immunotherapy Development: Greenwich Lifesciences' core business revolves around the development and potential commercialization of GP2, a HER2/neu-targeted immunotherapy. They are primarily focused on advancing GP2 through clinical trials for the prevention of breast cancer recurrence.
Leadership and Structure
As of the last update, Snehal Patel serves as the Chief Executive Officer. The company operates with a structure typical of a clinical-stage biotech, focusing on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- GP2 Immunotherapy: GP2 is Greenwich Lifesciences' lead product candidate, designed to prevent breast cancer recurrence. There is not currently market share data as GP2 is still in clinical trials. Key competitors would include companies developing preventative therapies for breast cancer recurrence, such as those focused on hormone therapies or other immunotherapies; however, no direct comparable prevention immunotherapy is on the market currently. Revenue associated with this product is currently $0 as it is in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is rapidly evolving, with a significant focus on cancer immunotherapy. The prevention of cancer recurrence is a growing area of interest.
Positioning
Greenwich Lifesciences is positioned as a developer of a novel immunotherapy approach to prevent breast cancer recurrence. The company's competitive advantage lies in its specific targeting of HER2/neu, a protein overexpressed in many breast cancers.
Total Addressable Market (TAM)
The breast cancer treatment market is substantial, estimated to be worth billions of dollars globally. Greenwich Lifesciences is positioned to capture a portion of the preventative treatment segment. The exact TAM is dependent on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Targeted treatment of HER2/neu-expressing breast cancers
- Potential to address a significant unmet need in preventing cancer recurrence
Weaknesses
- Reliance on a single product candidate (GP2)
- Clinical trial risk
- Limited financial resources relative to larger pharmaceutical companies
- Unproven commercial viability
Opportunities
- Successful completion of clinical trials
- Regulatory approval and commercialization of GP2
- Partnerships with larger pharmaceutical companies
- Expansion of GP2's application to other cancers expressing HER2/neu
Threats
- Clinical trial failure
- Competition from other therapies
- Regulatory hurdles
- Patent challenges
- Fund raising Risk
Competitors and Market Share
Key Competitors
- MRK
- PFE
- NVS
Competitive Landscape
Greenwich Lifesciences faces competition from established pharmaceutical companies with broader portfolios of cancer therapies. Their advantage lies in their novel immunotherapy approach, but they lack the resources of larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the progression of GP2 through clinical trials, not in revenue or earnings.
Future Projections: Future growth depends on the successful development and commercialization of GP2. Analyst projections are speculative and contingent on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include enrolling patients in Phase III clinical trials for GP2 and seeking partnerships for future commercialization.
Summary
Greenwich Lifesciences is a high-risk, high-reward clinical-stage biopharmaceutical company centered on GP2. Success hinges on positive clinical trial outcomes and regulatory approval. The company needs to demonstrate clinical efficacy and address fundraising challenges. Greenwich Lifesciences' targeted approach provides them with a competitive edge. They must navigate the regulatory and financial landscape successfully to benefit.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
The data and analysis provided are based on publicly available information and are for informational purposes only. It is not financial advice. Investments in biotech companies are highly speculative and involve significant risk. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Greenwich Lifesciences Inc
Exchange NASDAQ | Headquaters Stafford, TX, United States | ||
IPO Launch date 2020-09-25 | CEO, CFO & Director Mr. Snehal S. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.